1. Home
  2. TBBK vs HCM Comparison

TBBK vs HCM Comparison

Compare TBBK & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Bancorp Inc

TBBK

The Bancorp Inc

HOLD

Current Price

$52.75

Market Cap

2.5B

Sector

Finance

ML Signal

HOLD

Logo HUTCHMED (China) Limited

HCM

HUTCHMED (China) Limited

HOLD

Current Price

$12.70

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBBK
HCM
Founded
1999
2000
Country
United States
Hong Kong
Employees
N/A
1796
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.3B
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
TBBK
HCM
Price
$52.75
$12.70
Analyst Decision
Buy
Sell
Analyst Count
3
1
Target Price
$69.00
$13.75
AVG Volume (30 Days)
382.4K
27.2K
Earning Date
04-23-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
14.69
N/A
EPS
1.41
N/A
Revenue
$141,147,000.00
N/A
Revenue This Year
N/A
$20.60
Revenue Next Year
$8.16
$15.62
P/E Ratio
$38.07
$5.49
Revenue Growth
20.85
N/A
52 Week Low
$48.86
$12.53
52 Week High
$81.65
$19.50

Technical Indicators

Market Signals
Indicator
TBBK
HCM
Relative Strength Index (RSI) 32.38 28.98
Support Level $50.85 N/A
Resistance Level $55.74 $15.75
Average True Range (ATR) 1.99 0.32
MACD -0.93 -0.10
Stochastic Oscillator 5.07 10.38

Price Performance

Historical Comparison
TBBK
HCM

About TBBK The Bancorp Inc

The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, Credit Solutions (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Credit Solutions includes REBL (real estate bridge lending), comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.

About HCM HUTCHMED (China) Limited

HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.

Share on Social Networks: